Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors

Current Medicinal Chemistry

Volumn 21, Issue 9, 2014, Pages 1152-1159

  Pouplana, S ^a   Espargaro A ^b   Galdeano, C ^a   Viayna, E ^a   Sola, I ^a   Ventura, S ^b   Munoz Torrero D ^a   Sabate, R ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Alzheimer's disease; Amyloid formation; Bacterial inclusion bodies; Beta amyloid peptide; Conformational diseases; Tau protein; Thioflavin S

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PROTEIN; DONEPEZIL; PROPIDIUM IODIDE; PROTEIN INHIBITOR; TACRINE; TAU PROTEIN; THIOFLAVINE; VANILLIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BACTERIUM; CELL INCLUSION; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ESCHERICHIA COLI; IN VITRO STUDY; METHODOLOGY; NONHUMAN; PROTEIN AGGREGATION; QUANTITATIVE ANALYSIS; STAINING;

AMYLOID BETA-PEPTIDES; ESCHERICHIA COLI; HUMANS; INCLUSION BODIES; THIAZOLES; TIME FACTORS;

EID: 84896335260     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660256     Document Type: Article

References (58)

1. Aguzzi, A.; O'Connor, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov., 2010, 9, 237-248.
2. Bartolini, M.; Andrisano, V. Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem, 2010, 11, 1018-1035.
3. Goldschmidt, L.; Teng, P. K.; Riek, L.; Eisenberg, D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 3487-3492.
4. Carulla, N.; Caddy, G. L.; Hall, D. R.; Zurdo, J.; Gairí, M.; Feliz, M.; Giralt, E.; Robinson, C. V.; Dobson, C. M. Molecular recycling within amyloid fibrils. Nature, 2005, 436, 554-558. (Pubitemid 41112928)
5. Kodali, R.; Wetzel, R. Polymorphism in the intermediates and products of amyloid assembly. Curr. Opin. Struct. Biol, 2007, 17, 48-57. (Pubitemid 46242190)
6. Estrada, L. D.; Soto, C. Disrupting p-amyloid aggregation for Alzheimer's disease treatment. Curr. Top. Med. Chem., 2007, 7, 115-126. (Pubitemid 46062400)
7. Hammer, N. D.; Wang, X.; McGuffie, B. A.; Chapman, M. R. Amyloids: friend or foe? J. Alzheimer Dis., 2008, 13, 407-419. (Pubitemid 352039020)
8. Chiti, F.; Dobson, CM. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem., 2006, 75, 333-366. (Pubitemid 44118036)
9. Selkoe, DJ. The molecular pathology of Alzheimer's disease. Neuron, 1991, 6, 487-498.
10. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-185.
11. Hardy, J.; Selkoe, DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-356. (Pubitemid 34790756)
12. Pimplikar, S. W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol, 2009, 41, 1261-1268.
13. Hawkes, C. A.; Ng, V.; McLaurin, J. Small molecule inhibitors of Ap aggregation and neurotoxicity. Drug Dev. Res., 2009, 70, 111-124.
14. Re, F.; Airoldi, C; Zona, C; Masserini, M.; La Ferla, B.; Quattrocchi, N.; Nicotra, F. Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease. Curr. Med. Chem., 2010, 17, 2990-3006.
15. Valensin, D.; Gabbiani, C; Messori, L. Metal compounds as inhibitors of p-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease. Coord. Chem. Rev., 2012, 256, 2357-2366.
16. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. Chem. Rev., 2012, 112, 5147-5192.
17. Tayeb, H. O.; Yang, H. D.; Price, B. H.; Tarazi, F. I. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol. Ther., 2012, 134, 8-25.
18. Le Vine, H., III. Thioflavine T interaction with synthetic Alzheimer's disease/J-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci., 1993, 2, 404-410. (Pubitemid 23071288)
19. Bartolini, M.; Bertucci, C; Cavrini, V.; Andrisano, V. p-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol, 2003, 65, 407-416. (Pubitemid 36084557)
20. Bartolini, M.; Bertucci, C; Bolognesi, M. L.; Cavalli, A.; Melchiorre, C; Andrisano, V. Insight into the kinetic of amyloid/J (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. ChemBioChem, 2007, 8, 2152-2161. (Pubitemid 350220767)
21. Akaishi, T.; Morimoto, T.; Shibao, M.; Watanabe, S.; Sakai-Kato, K.; Utsunomiya-Tate, N.; Abe, K. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein. Neurosci. Lett., 2008, 444, 280-285.
22. Veloso, A. J.; Dhar, D.; Chow, A. M.; Zhang, B.; Tang, D. W. F.; Ganesh, H. V. S.; Mikhaylichenko, S.; Brown, I. R.; Kerman, K. sym-Triazines for directed multitarget modulation of cholinesterases and amyloid-p in Alzheimer's disease. ACS Chem. Neurosci., 2013, 4, 339-349.
23. Barabási, A. L.; Oltvai, Z. N.; Network biology: understanding the cell's functional organization. Nat. Rev. Genet., 2004, 5, 101-113. (Pubitemid 38160277)
24. Viayna, E.; Sola, I.; Di Pietro, O.; Muñoz-Torrero, D. Human disease and drug pharmacology, complex as real life. Curr. Med. Chem., 2013, 20, 1623-1634.
25. Lee, J. A.; Uhlik, M. T.; Moxham, CM.; Tomandl, D.; Sall, DJ. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem., 2012, 55, 4527-4538.
26. Ellis, R. J.; Minton, A. P. Join the crowd. Nature, 2003, 425, 27-28. (Pubitemid 37101701)
27. Ami, D.; Natalello, A.; Lotti, M.; Doglia, S. M. Why and how protein aggregation has to be studied in vivo. Microb. Cell Fact., 2013, 12, 17.
28. Villar-Piqué, A.; Ventura, S. Modeling amyloids in bacteria. Microb. Cell Fact., 2012, 11, 166.
29. Ventura, S.; Villaverde, A. Protein quality in bacterial inclusion bodies. Trends Biotechnol, 2006, 24, 179-185.
30. de Groot, N. S.; Sabate, R.; Ventura, S. Amyloids in bacterial inclusion bodies. Trends Biochem. Sci., 2009, 34, 408-416.
31. Wang, L.; Maji, S. K.; Sawaya, M. R.; Eisenberg, D.; Riek, R. Bacterial inclusion bodies contain amyloid-like structure. PLoS Biol, 2008, 6, e195.
32. Dasari, M.; Espargaro, A.; Sabate, R.; Lopez del Amo, J. M.; Fink, U.; Grelle, G.; Bieschke, J.; Ventura, S.; Reif, B. Bacterial inclusion bodies of Alzheimer's disease (3-amyloid peptides can be employed to study native-like aggregation intermediate states. ChemBioChem, 2011, 12, 407-423.
33. Carrió, M.; González-Montalbán, N.; Vera, A.; Villaverde, A.; Ventura, S. Amyloid-like properties of bacterial inclusion bodies. J. Mol. Biol, 2005, 347, 1025-1037. (Pubitemid 40387450)
34. Villar-Piqué, A.; Espargaró, A.; Sabaté, R.; de Groot, N. S.; Ventura, S. Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors. Microb. Cell Fact., 2012, 11, 55.
35. Espargaró, A.; Sabate, R.; Ventura, S. Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation. Mol. Biosyst., 2012, 8, 2839-2844.
36. Spólnik, P.; Stopa, B.; Piekarska, B.; Jagusiak, A.; Konieczny, L.; Rybarska, J.; Król, M.; Roterman, I.; Urbanowicz, B.; Zieba-Palus, J. The use of rigid, fibrillar Congo red nanostructures for scaffolding protein assemblies and inducing the formation of amyloid-like arrangement of molecules. Chem. Biol. Drug Des., 2007, 70, 491-501. (Pubitemid 350150871)
37. Darghal, N.; Garnier-Suillerot, A.; Salerno, M. Mechanism of thioflavin T accumulation inside cells overexpressing P-glycoprotein or multidrug resistance-associated protein: role of lipophilicity and positive charge. Biochem. Biophys. Res. Commun., 2006, 343, 623-629.
38. Le Vine, H., III. Quantification of (3-sheet amyloid fibril structures with thioflavin T. Methods Enzymol, 1999, 309, 274-284. (Pubitemid 29446455)
39. De Felice, F. G.; Houzel, J.-C; Garcia-Abreu, J.; Louzada, P. R. F., Jr.; Afonso, R. C.; Meirelles, M. N. L.; Lent, R.; Neto, V. M.; Ferreira, S. T. Inhibition of Alzheimer's disease (3-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. FASEB J., 2001, 15, 1297-1299.
40. Urbanc, B.; Cruz, L.; Le, R.; Sanders, J.; Hsiao Ashe, K.; Duff, K.; Stanley, H. E.; Irizarry, M. C.; Hyman, B. T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 13990-13995. (Pubitemid 35257612)
41. Camps, P.; El Achab, R.; Morral, J.; Muñoz-Torrero, D.; Badia, A.; Baños, J. E.; Vivas, N. M.; Barril, X.; Orozco, M.; Luque, FJ. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J. Med. Chem., 2000, 43, 4657-4666.
42. Camps, P.; Formosa, X.; Galdeano, C; Muñoz-Torrero, D.; Ramírez, L.; Gómez, E.; Isambert, N.; Lavilla, R.; Badia, A.; Clos, M. V.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez-Franco, M. I.; Huertas, O.; Dafni, T.; Luque, FJ. Pyrano[3, 2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and/J-amyloid-directed anti-Alzheimer compounds. J. Med. Chem., 2009, 52, 5365-5379.
43. Galdeano, C; Viayna, E.; Sola, I.; Formosa, X.; Camps, P.; Badia, A.; Clos, M. V.; Relat, J.; Ratia, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Salmona, M.; Minguillón, C; González-Muñoz, G. C.; Rodríguez-Franco, M. I.; Bidon-Chanal, A.; Luque, FJ.; Muñoz-Torrero, D. Huprine-tacrine heterodimers as antiamyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J. Med. Chem., 2012, 55, 661-669.
44. Viayna, E.; Gómez, T.; Galdeano, C; Ramírez, L.; Ratia, M.; Badia, A.; Clos, M. V.; Verdaguer, E.; Junyent, F.; Camins, A.; Pallàs, M.; Bartolini, M.; Mancini, F.; Andrisano, V.; Arce, M. P.; Rodríguez- Franco, M. I.; Bidon-Chanal, A.; Luque, FJ.; Camps, P.; Muñoz-Torrero, D. Novel huprine derivatives with inhibitory activity toward (3-amyloid aggregation and formation as diseasemodifying anti-Alzheimer drug candidates. ChemMedChem, 2010, 5, 1855-1870.
45. Sabaté, R.; Estelrich, J. Disaggregating effects of ethanol at low concentration on beta-poly-L-lysines. Int. J. Biol. Macromol, 2003, 32, 10-16. (Pubitemid 36444513)
46. Markarian, S. A.; Poladyan, A. A.; Kirakosyan, G. R.; Trchounian, A. A.; Bagramyan, K. A. Effect of diethylsulphoxide on growth, survival and ion exchange of Escherichia coli. Lett. Appl. Microbiol, 2002, 34, 417-421. (Pubitemid 34534229)
47. Wadhwani, T.; Desai, K.; Patel, D.; Lawani, D.; Bahaley, P.; Joshi, P.; Kothari, V. Effect of various solvents on bacterial growth in context of determining MIC of various antimicrobials. Internet J. Microbiol, 2009, 7 (1). DOI: 10.5580/b43.
48. Balguerie, A.; Dos Reis, S.; Ritter, C; Chaignepain, S.; Coulary-Salin, B.; Forge, V.; Bathany, K.; Lascu, I.; Schmitter, J.-M.; Riek, L.; Saupe, SJ. Domain organization and structure-function relationship of the HET-s prion protein of Podospora anserina. EMBO J., 2003, 22, 2071-2081. (Pubitemid 36565532)
49. Bolognesi, M. L.; Banzi, R.; Bartolini, M.; Cavalli, A.; Tarozzi, A.; Andrisano, V.; Minarini, A.; Rosini, M.; Tumiatti, V.; Bergamini, C; Fato, R.; Lenaz, G.; Hrelia, P.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. J. Med. Chem., 2007, 50, 4882-4897. (Pubitemid 47525472)
50. Necula, M.; Kayed, R.; Milton, S.; Glabe, C. G. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem., 2007, 282, 10311-10324. (Pubitemid 47093410)
51. Zhang, H.-Y. Same causes, same cures. Biochem. Biophys. Res. Commun., 2006, 351, 578-581. (Pubitemid 44708866)
52. de Groot, N. S.; Ventura, S. Protein activity in bacterial inclusion bodies correlates with predicted aggregation rates. J. Biotechnol, 2006, 125, 110-113. (Pubitemid 44066612)
53. Espargaro, A.; Castillo, V.; de Groot, N. S.; Ventura, S. The in vivo and in vitro aggregation properties of globular proteins correlate with their conformational stability: the SH3 case. J. Mol. Biol, 2008, 378, 1116-1131.
54. Calloni, G.; Zoffoli, S.; Stefani, M.; Dobson, CM.; Chiti, F. Investigating the effects of mutations on protein aggregation in the cell. J. Biol. Chem., 2005, 280, 10607-10613. (Pubitemid 40395922)
55. Mayer, S.; Rudiger, S.; Ang, H. C.; Joerger, A. C.; Fersht, A. R. Correlation of levels of folded recombinant p53 in Escherichia coli with thermodynamic stability in vitro. J. Mol. Biol, 2007, 372, 268-276. (Pubitemid 47223226)
56. Kim, W.; Kim, Y.; Min, J.; Kim, D. J.; Chang, Y. T.; Hecht, M. H. A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem. Biol, 2006, 1, 461-469.
57. Liu, R.; Su, R.; Liang, M.; Huang, R.; Wang, M.; Qi, W.; He, Z. Physicochemical strategies for inhibition of amyloid fibril formation: an overview of recent advances. Curr. Med. Chem., 2012, 19, 4157-4174.
58. Speck-Planche, A.; Luan, F.; Cordeiro, M. N. Role of ligand-based drug design methodologies toward the discovery of new anti-Alzheimer agents: futures perspectives in fragment-based ligand design. Curr. Med. Chem., 2012, 19, 1635-1645.